• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Covidien subsidiary VNUS wins $46 million in patent trial

Covidien subsidiary VNUS wins $46 million in patent trial

December 11, 2010 By MassDevice staff

COV logo

A federal jury in San Francisco awarded Covidien plc (MKT:COV) subsidiary VNUS Medical Technologies Inc. $46 million in a patent infringement trial over a laser-based method for treating varicose veins.

The verdict in the U.S. District Court for Northern California went against Total Vein Solutions LLC and Biolitec AG, which must pay $36.5 and $9.3 million, respectively.

Houston-based TVS plans to challenge the jury’s decision, which also invalidated some of VNUS’s patent claims for a endovenous laser ablation method.

"[Total Vein] agrees with the jury’s findings that certain claims in VNUS’ ‘084, ‘803 and ‘355 patents were invalid," president Tyri Schiek said in prepared remarks.

"TVS will continue business as usual and is confident that those findings of the jury that were in error will be overturned, either by the trial court or at the appellate level," CEO David Centanni said in prepared remarks. He called the damages awarded to VNUS "grossly inflated."

VNUS began its litigation against TVS and Jena, Germany-based surgical and cosmetic laser developer Biolitec in 2008 for "indirect patent infringement, by way of contributory and induced infringement," according to TVS. The suits related to TVS’ sales of laser fibers, laser consoles, introducer kits and procedure packs, according to the company. TVS claims that its sales of unpatented products amount to infringing conduct and that the patents in question don’t adequately enable doctors to perform their methods of laser ablation.

"We are pleased that the jury found that Total Vein Solutions and Biolitec willfully infringed our patents. It is our responsibility to protect our intellectual property. This decision supports our commitment to innovation and to provide our customers wih the best possible solutions to treat their patients," Covidien spokesperson Rachel Bloom Baglin told MassDevice.

The Mansfield, Mass.-based company acquired VNUS in May 2009 for $440 million.

Earlier this week, a German court awarded Covidien with preliminary injunctions against one British and four Chinese firms in a patent spat over surgical stapling devices.

Filed Under: Business/Financial News, Cosmetic/Aesthetic, Dental, Legal News, News Well, Patent Infringement Tagged With: Biolitec, Covidien, Total Vein Solutions LLC

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy